BioSpecifics Story

<div class='circular--portrait' style='background:#3b5998;color: #F0F8FF;font-size:4em;'>BT</div>
BSTC -- USA Stock  

USD 51.94  0.44  0.84%

BioSpecifics Technologies Net Income Per Employee is projected to increase significantly based on the last few years of reporting. The past year's Net Income Per Employee was at 3.5 Million. The current year Average Assets is expected to grow to about 124.9 M, whereas Revenue Per Employee is forecasted to decline to about 4.5 M. If you have been following BioSpecifics you may be considering taking in. Let's check if strong basic indicators will continue to push the price to rise for BioSpecifics Technologies' investors. Will investors continue to hold, or should we expect a sell-off?
Published over a month ago
View all stories for BioSpecifics Technologies | View All Stories
How strong are BioSpecifics Technologies (NASDAQ:BSTC) basic indicators given the current rise?
BioSpecifics Technologies is UNDERVALUED at 76.40 per share with modest projections ahead. BioSpecifics Technologies appears to be very steady, given 1 month investment horizon. BioSpecifics Technologies secures Sharpe Ratio (or Efficiency) of 0.0771, which signifies that the company had 0.0771% of return per unit of risk over the last month. Our standpoint towards foreseeing the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-eight technical indicators for BioSpecifics Technologies Corp, which you can use to evaluate future volatility of the firm. Please makes use of BioSpecifics Technologies Risk Adjusted Performance of 0.1481, downside deviation of 2.6, and Mean Deviation of 2.11 to double-check if our risk estimates are consistent with your expectations.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include BioSpecifics Technologies income statement, its balance sheet, and the statement of cash flows. Potential BioSpecifics Technologies investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although BioSpecifics Technologies investors may use each financial statement separately, they are all related. The changes in BioSpecifics Technologies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioSpecifics Technologies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of BioSpecifics Technologies fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of BioSpecifics Technologies performance into the future periods or doing a reasonable stock valuation. The intrinsic value of BioSpecifics Technologies shares is the value that is considered the true value of the share. If the intrinsic value BioSpecifics is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares BioSpecifics Technologies. Please read more on our fundamental analysis page.

Are BioSpecifics Technologies Earnings Expected to grow?

The future earnings power of BioSpecifics Technologies involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of BioSpecifics Technologies factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. BioSpecifics Technologies stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of BioSpecifics expected earnings.

How BioSpecifics utilizes its cash?

To perform a cash flow analysis of BioSpecifics Technologies, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash BioSpecifics Technologies is receiving and how much cash it distributes out in a given period. The BioSpecifics Technologies cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. BioSpecifics Technologies Net Cash Flow from Operations is projected to increase significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at 22.29 Million

BioSpecifics Technologies Gross Profit

BioSpecifics Technologies Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing BioSpecifics Technologies previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show BioSpecifics Technologies Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Acquisition by Jennifer Chao of 1726 shares of BioSpecifics Technologies subject to Rule 16b-3

Legal trades by BioSpecifics Technologies insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
BioSpecifics insider trading alert for grant of common stock $0.001 par value by Jennifer Chao, the corporate stakeholder, on 17th of July 2020. This event was filed by Biospecifics Technologies with SEC on 2020-07-17. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Going after BioSpecifics Financials

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of BioSpecifics Technologies is not uncomon. There are few distinct groups of BioSpecifics Technologies stakehholders that the SEC considers insiders. Investors usually gain information through their work as corporate directors, officers, or employees. If these individuals share the information with a friend, family, or business partner and the person who receives the information exchanges stock in the company, he or shie is also an insider. Let's take a look at how the ownership of BioSpecifics is distributed among investors.

Ownership Allocation

The market capitalization of BioSpecifics Technologies is $481.32 Million. Over half of BioSpecifics Technologies outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in BioSpecifics Technologies. Please watch out for any change in the institutional holdings of BioSpecifics Technologies as this could mean something significant has changed or about to change at the company. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.

Retail Investors
7.11%
Insiders
26.15%
Institutions
66.74%
Retail Investors7.11
Insiders26.15
Institutions66.74
 2019 2020 (projected)
Interest Expense35.134.89
Gross Profit38.19 M31.02 M

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BioSpecifics Technologies has an asset utilization ratio of 86.94 percent. This suggests that the company is making $0.87 for each dollar of assets. An increasing asset utilization means that BioSpecifics Technologies Corp is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
117.9 M
Current Assets117.9 Million85.74
Assets Non Current18.75 Million13.64
Goodwill476,8810.35
Tax Assets370,3290.27

Another 3 percent rise for BioSpecifics Technologies

Current variance is at 8.23. As of the 8th of August, BioSpecifics Technologies shows the Risk Adjusted Performance of 0.1481, mean deviation of 2.11, and Downside Deviation of 2.6. BioSpecifics Technologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for BioSpecifics Technologies Corp, which can be compared to its rivals. Please confirm BioSpecifics Technologies jensen alpha, as well as the relationship between the potential upside and skewness to decide if BioSpecifics Technologies is priced correctly, providing market reflects its regular price of 65.53 per share. Given that BioSpecifics Technologies has jensen alpha of 0.313, we suggest you to validate BioSpecifics Technologies Corp's prevailing market performance to make sure the company can sustain itself at a future point.

Our Final Perspective on BioSpecifics Technologies

Whereas some other companies under the biotechnology industry are still a bit expensive, BioSpecifics Technologies may offer a potential longer-term growth to investors. The inconsistency in the assessment between current BioSpecifics valuation and our trade advice on BioSpecifics Technologies is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to BioSpecifics Technologies.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of BioSpecifics Technologies Corp. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com